Regular Article
Expression, Purification, and Characterization of a Catalytically Active Human Cytochrome P450 1A2:Rat NADPH-Cytochrome P450 Reductase Fusion Protein

https://doi.org/10.1006/prep.1997.0721Get rights and content

Abstract

An enzymatically active human cytochrome P450 (P450) 1A2:rat NADPH-P450 reductase fusion protein was purified and partially characterized following heterologous expression inEscherichia coli. A cDNA was engineered to include the coding sequence for human P450 1A2 at its 5′ end (up to but not including the stop codon) fused in-frame to the coding sequence for a truncated (soluble) rat NADPH-P450 reductase at its 3′ end via an oligonucleotide sequence encoding the hydrophilic dipeptide Ser–Thr. This fusion plasmid was expressed inE. coliand the recombinant protein was purified from the detergent-solubilized membrane fraction via sequential DEAE, ADP–agarose, and hydroxylapatite chromatographies. The purified protein has the spectral characteristics of human P450 1A2 and cytochromecreduction activity comparable to rabbit NADPH-P450 reductase. The fusion protein catalyzed 7-ethoxyresorufinO-deethylation and phenacetinO-deethylation to appreciable levels in the presence of NADPH and phospholipid. While these activities were comparable to those of other such P450:NADPH-P450 reductase fusion proteins, they were lower than those of the system reconstituted from its individual hemoprotein and flavoprotein components. Nevertheless, the production of a functional, catalytically self-sufficient monooxygenase inE. colienhances the prospect of using bacterial systems for production and characterization of human P450 drug metabolites as well as for biodegradation of chemicals in the environment.

References (54)

  • T. Omura et al.

    The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature

    J. Biol. Chem.

    (1964)
  • Y. Yasukochi et al.

    Some properties of a detergent-solubilized NADPH-cytochromec

    J. Biol. Chem.

    (1976)
  • W. Wray et al.

    Silver staining of proteins in polyacrylamide gels

    Anal. Biochem.

    (1981)
  • L.M. Distlerath et al.

    Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism

    J. Biol. Chem.

    (1985)
  • E.M.J. Gillam et al.

    Expression of cytochrome P450 2D6 inEscherichia coli,

    Arch. Biochem. Biophys.

    (1995)
  • T.D. Porter et al.

    Expression of a functional 78,000 dalton mammalian flavoprotein, NADPH-cytochrome P-450 oxidoreductase, inEscherichia coli

    Arch. Biochem. Biophys.

    (1987)
  • T. Omura et al.

    Isolation of cytochromes P-450 and P-420

    Methods Enzymol.

    (1967)
  • Y. Higashi et al.

    Effects of individual mutations in the P-450 (C21) pseudogene on the P-450 (C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency

    J. Biochem.

    (1991)
  • W.L. Miller et al.

    The molecular genetics of 21-hydroxylase deficiency

    Annu. Rev. Genet.

    (1989)
  • P.C. White et al.

    A mutation in CYP11Ba (Arg 448—His) associated with steroid 11β-hydroxylase deficiency in Jews of Moroccan origin

    J. Clin. Invest.

    (1991)
  • R.L. Woosley et al.

    Mechanism of the cardiotoxic actions of terfenadine

    J. Am. Med. Assoc.

    (1993)
  • F.P. Guengerich

    Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy

    Cancer Res.

    (1988)
  • F.P. Guengerich

    Characterization of roles of human cytochrome P-450 enzymes in carcinogen metabolism

    Asia Pacific J. Pharmacol.

    (1990)
  • F.P. Guengerich

    Metabolic activation of carcinogens

    Pharmacol. Ther.

    (1992)
  • T. Shimada et al.

    Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens

    Mol. Pharmacol.

    (1992)
  • T. Sakaki et al.

    Monooxygenase activity ofSaccharomyces cerevisiae

    J. Biochem.

    (1986)
  • Cited by (29)

    • A tricistronic human adrenodoxin reductase-adrenodoxin-cytochrome P450 27A1 vector system for substrate hydroxylation in Escherichia coli

      2011, Protein Expression and Purification
      Citation Excerpt :

      This result suggests that the tricistronic expression vector in E. coli was effective for the simultaneous expression of the three components between 24 and 48 h following incubation. It has been reported elsewhere that P450 expression can be modulated by co-expression together with other proteins, and its content levels are higher when the P450 is expressed monocistronically [35]. Using the multiple expression method with the tricistronic vector, it was possible to express P450 27A1 to a level of 330 nmol/L of culture medium when coexpressed with Adx and Adr in the tricistronic system (as judged by spectral analysis after 48 h, Supplementary Data Fig. S-1), which we considered adequate for further studies (the level was 300 nmol/L in a separate experiment).

    • Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5

      2011, Biochemical Pharmacology
      Citation Excerpt :

      For human liver microsomes, NADPH-cytochrome c reduction activities were determined as described previously [35]. P450 reductase concentrations were calculated assuming a specific activity of 3.0 μmol of cytochrome c reduced per minute per nanomole of reductase, based on published data for purified human and rabbit reductase preparations [15]. The concentration of cytochrome b5 was calculated spectrally following published methods [28,36].

    View all citing articles on Scopus

    P. GarriguesM. Lamotte, Eds.

    1

    To whom correspondence and reprint requests should be addressed.

    View full text